| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
INSERM U 334, Service Hospitalier Frédéric Joliot
A. Chenevier Hôpital, Créteil, and INSERM U 334, Service Hospitalier Frédéric Joliot, Orsay
INSERM U 334, Service Hospitalier Frédéric Joliot, Orsay
Pitié-Salpêtrière Hôpital, Paris, France
Correspondence: Jean-Luc Martinot, INSERUM U 334, SHFJ, CEA, 4 Place Gl. Leclerc, 91401 Orsay, France. E-mail: martinot{at}shfj.cea.fr
Declaration of interest The Fondation pour la Recherche Médicale and the Fondation Lilly France supported X.X. in part during the study.
* Presented in part at the VIIth International Congress on Schizophrenia Research, Santa Fe, New Mexico, USA, 17-21 April 1999.
Background Both traditional and atypical antipsychotics have been hypothesised to be effective in schizophrenia through limbic and cortical D2 dopamine receptor blockade.
Aims To investigate this hypothesis with the D2/D3-selective positron emission tomography (PET) probe [76Br]-FLB457.
Method PET scans were performed on 6 controls and 18 patients with schizophrenia treated with haloperidol or with risperidone, clozapine, amisulpride or olanzapine.
Results The D2 dopamine receptor blockade was high in the temporal cortex with both haloperidol and atypical antipsychotics. The atypicals, however, induced a significantly lower D2 binding index than haloperidol in the thalamus and in the striatum.
Conclusions Results suggest that cortical D2 dopamine receptors are a common target of traditional and atypical antipsychotics for therapeutic action. Higher in vivo binding to the D2 receptors in the cortex than in the basal ganglia is suggested as an indicator of favourable profile for a putative antipsychotic compound.
Related articles in BJP:
This article has been cited by other articles:
|
|
 |
|
  G. Grunder, C. Fellows, H. Janouschek, T. Veselinovic, C. Boy, A. Brocheler, K. M. Kirschbaum, S. Hellmann, K. M. Spreckelmeyer, C. Hiemke, et al. Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [18F]Fallypride PET Study Am J Psychiatry, August 1, 2008; 165(8): 988 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature Schizophr Bull, February 26, 2008; (2008) sbn009v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Drew, E. H. Simpson, C. Kellendonk, W. G. Herzberg, O. Lipatova, S. Fairhurst, E. R. Kandel, C. Malapani, and P. D. Balsam Transient Overexpression of Striatal D2 Receptors Impairs Operant Motivation and Interval Timing J. Neurosci., July 18, 2007; 27(29): 7731 - 7739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]
|
|
|
|
|
|
R. Mizrahi, P. Rusjan, O. Agid, A. Graff, D. C. Mamo, R. B. Zipursky, and S. Kapur Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D2 Receptors: a PET Study in Schizophrenia Am J Psychiatry, April 1, 2007; 164(4): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone Am J Psychiatry, March 1, 2006; 163(3): 396 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al. Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine J Psychopharmacol, September 1, 2004; 18(3): 355 - 365. [Abstract] [PDF]
|
|
|
|
|
|
D. Mamo, S. Kapur, C. M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone Am J Psychiatry, May 1, 2004; 161(5): 818 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lorberboym, N. Watemberg, A. Nissenkorn, B. Nir, and T. Lerman-Sagie Technetium 99m Ethylcysteinate Dimer Single-Photon Emission Computed Tomography (SPECT) During Intellectual Stress Test in Children and Adolescents With Pure Versus Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) J Child Neurol, February 1, 2004; 19(2): 91 - 96. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Bressan, K. Erlandsson, H. M. Jones, R. Mulligan, R. J. Flanagan, P. J. Ell, and L. S. Pilowsky Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients Am J Psychiatry, August 1, 2003; 160(8): 1413 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Sullivan, M. J. Rosenbloom, K. L. Serventi, A. Deshmukh, and A. Pfefferbaum Effects of Alcohol Dependence Comorbidity and Antipsychotic Medication on Volumes of the Thalamus and Pons in Schizophrenia Am J Psychiatry, June 1, 2003; 160(6): 1110 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. JONES and L. S. PILOWSKY Dopamine and antipsychotic drug action revisited The British Journal of Psychiatry, October 1, 2002; 181(4): 271 - 275. [Full Text] [PDF]
|
|
|
|
|
|
M. Kopecek, C. Hoschl, T. Hajek, J. L. Martinot, X. Xiberas, E. Artiges, C. Loc'h, B. Maziere, and M. L. Paillere Regional selectivity of novel antipsychotics * Authors' reply The British Journal of Psychiatry, September 1, 2002; 181 (3): 254 - 255. [Full Text]
|
|
|
|
|
|
S. Kapur and P. Seeman Atypical antipsychotics, cortical D2 receptors and sensitivity to endogenous dopamine The British Journal of Psychiatry, May 1, 2002; 180 (5): 465 - 466. [Full Text] [PDF]
|
|
|
|
|
|
L. S. PILOWSKY and P. J. ELL Clozapine and dopamine D(2) blockade. Am J Psychiatry, February 1, 2002; 159(2): 324 - 325. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
